Epidemiology and Characteristics of Episodic Breathlessness in @entity5 XXXX : An Observational Study.

@entity1 @entity1353 @entity5 @entity1820 @entity1030
CONTEXT: Episodic @entity1353 is a relevant aspect in @entity1 with @entity5 . OBJECTIVES: The aim of this study was to assess the different aspects of this clinical phenomenon. METHODS: A consecutive sample of @entity1 with @entity5 admitted to different settings for a period of six months was surveyed. The presence of background @entity1353 and episodic @entity1353 , their intensity (numerical scale 0-10), and drugs used for treatment were collected. Factors inducing episodic @entity1353 and its influence on daily activities were investigated. RESULTS: Of 921 @entity1 , 29.3% (n  =  269) had @entity1353 and 134 @entity1 (49.8%) were receiving drugs for background @entity1353 . In the multivariate analysis, the risk of @entity1353 increased with @entity1030 , although it decreased in @entity1 receiving disease-oriented therapy and @entity1 with @entity1820 . The prevalence of episodic @entity1353 was 70.9% (n  =  188), and its mean intensity was 7.1 (SD 1.6). The mean  duration of untreated episodic @entity1353 was 19.9  minutes (SD 35.3); 41% of these @entity1 were receiving drugs  for episodic @entity1353 . The majority of episodic @entity1353 events (88.2%) were triggered by activity. In the multivariate analysis, higher Karnofsky Performance Status levels were significantly related to episodic @entity1353 , although @entity1 receiving disease-oriented therapy were less likely to have episodic @entity1353 . CONCLUSION: This study showed that episodic @entity1353 frequently occurs in @entity1 with @entity1353 in the advanced stage of disease, has a severe intensity, and is characterized by rapid onset and short duration, which require rapid measures.
